Literature DB >> 7176648

A sensitive radioimmunoassay for budesonide in plasma.

G W Aherne, P Littleton, A Thalen, V Marks.   

Abstract

Budesonide is a highly potent non-halogenated glucocorticoid with local anti-inflammatory properties. A sensitive radioimmunoassay for the measurement of the drug in unextracted plasma has been developed. Budesonide 21-hemisuccinate and budesonide 3-(O-carboxymethyl)oxime were conjugated to ovalbumin using the mixed anhydride method and antibodies to the haptens produced in sheep. The specificity of the antisera towards cortisol, and possible budesonide metabolites reflected the different sites of the attachment of the haptens to the carrier protein. An antiserum raised against the 3-(O-carboxy methyl)oxime conjugate was more specific (0.001% cross reaction) with respect to cortisol than the antiserum raised against the 21-hemisuccinate conjugate (0.344% cross reaction). Endogenous steroids at concentrations normally encountered in clinical samples, would not interfere with the measurement of budesonide. The radioimmunoassay was developed using the budesonide 3-(O-carboxy methyl)oxime antiserum, [3H]-budesonide and dextran coated charcoal phase separation. The theoretical limit of detection of the assay was 50 pg/ml. Budesonide was quantitatively recovered from normal human drug/free plasma at concentrations above 1 ng/ml (2.32 nmol/l) with a between batch variation of 12-15%. Budesonide was measured in the unextracted plasma of volunteers who had inhaled the drug from a pressurised aerosol spray.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7176648     DOI: 10.1016/0022-4731(82)90016-4

Source DB:  PubMed          Journal:  J Steroid Biochem        ISSN: 0022-4731            Impact factor:   4.292


  4 in total

1.  A rat model for testing anti-inflammatory action in lung and the effect of glucocorticosteroids (GCS) in this model.

Authors:  L Källström; R Brattsand; U Lövgren; E Svensjö; K Roempke
Journal:  Agents Actions       Date:  1986-01

Review 2.  Pharmacokinetics of budesonide (Entocort EC) capsules for Crohn's disease.

Authors:  Staffan Edsbäcker; Tommy Andersson
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

3.  Pharmacokinetics of budesonide in children with asthma.

Authors:  S Pedersen; G Steffensen; I Ekman; M Tönnesson; O Borgå
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

Review 4.  Budesonide. A preliminary review of its pharmacodynamic properties and therapeutic efficacy in asthma and rhinitis.

Authors:  S P Clissold; R C Heel
Journal:  Drugs       Date:  1984-12       Impact factor: 9.546

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.